OpenEvidence has closed its $210 million Series B funding round at a $3.5 billion valuation as Google Ventures and Kleiner Perkins leads its investments. The Cambridge-based medical AI company has raised over $300 million since its establishment, and today more than 40% of US physicians log in to make clinical decisions every day.
The platform operates in more than 10,000 hospitals and medical centers nationwide, with over 65,000 new, verified US clinical doctor registrations each month. In July 2024, OpenEvidence supported consultations from around 358,000 logged in doctors in a month. A year later, the platform will process that volume for each volume.
OpenEvidence DeepConsult targets complex medical research
OpenEvidence has announced a wide range of releases of OpenEvidence DeepConsult, described as the first AI agent for doctors. The system uses inference models to autonomously analyze and cross-reference hundreds of peer-reviewed medical research in parallel, and provides comprehensive research reports that require months of human effort.
Running each DeepConsult requires more than 100 times the calculation and cost of a standard OpenEvidence search. While some foundation model companies have publicly speculated about charging tens of thousands of dollars a month for PHD-level agents still in development, OpenEvidence is offered free of charge to all verified US clinicians.
“When US healthcare faces the dual challenges of clinician burnout and the shortage of nearly 100,000 doctors by 2030, the issue of AI's role in filling the gap is paramount.” “When doctors live their lives are difficult, patients' lives are even more difficult.”
